<?xml version='1.0' encoding='utf-8'?>
<document id="20377319"><sentence text="Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects."><entity charOffset="42-65" id="DDI-PubMed.20377319.s1.e0" text="eslicarbazepine acetate" /><entity charOffset="70-80" id="DDI-PubMed.20377319.s1.e1" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.20377319.s1.e0" e2="DDI-PubMed.20377319.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s1.e0" e2="DDI-PubMed.20377319.s1.e1" /></sentence><sentence text="Combination therapy is frequently required in the management of epilepsy" /><sentence text=" The primary objective of this study was to investigate the pharmacokinetic interaction between eslicarbazepine acetate (ESL) 1200 mg once daily and topiramate (TPM) 200 mg once daily in healthy subjects"><entity charOffset="96-119" id="DDI-PubMed.20377319.s3.e0" text="eslicarbazepine acetate" /><entity charOffset="121-124" id="DDI-PubMed.20377319.s3.e1" text="ESL" /><entity charOffset="149-159" id="DDI-PubMed.20377319.s3.e2" text="topiramate" /><entity charOffset="161-164" id="DDI-PubMed.20377319.s3.e3" text="TPM" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e0" e2="DDI-PubMed.20377319.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e0" e2="DDI-PubMed.20377319.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e0" e2="DDI-PubMed.20377319.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e0" e2="DDI-PubMed.20377319.s3.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e1" e2="DDI-PubMed.20377319.s3.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e1" e2="DDI-PubMed.20377319.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e1" e2="DDI-PubMed.20377319.s3.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e2" e2="DDI-PubMed.20377319.s3.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s3.e2" e2="DDI-PubMed.20377319.s3.e3" /></sentence><sentence text="" /><sentence text="Multiple-dose, open-label, one-sequence study in two parallel groups of 16 healthy male volunteers" /><sentence text=" After an 8-day treatment with ESL (Group A) or TPM (Group B), ESL and TPM were co-administered for 19 days"><entity charOffset="31-33" id="DDI-PubMed.20377319.s6.e0" text="ESL" /><entity charOffset="63-65" id="DDI-PubMed.20377319.s6.e1" text="ESL" /><entity charOffset="48-50" id="DDI-PubMed.20377319.s6.e2" text="TPM" /><entity charOffset="71-73" id="DDI-PubMed.20377319.s6.e3" text="TPM" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e0" e2="DDI-PubMed.20377319.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e0" e2="DDI-PubMed.20377319.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e0" e2="DDI-PubMed.20377319.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e0" e2="DDI-PubMed.20377319.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e2" e2="DDI-PubMed.20377319.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e2" e2="DDI-PubMed.20377319.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e2" e2="DDI-PubMed.20377319.s6.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e1" e2="DDI-PubMed.20377319.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s6.e1" e2="DDI-PubMed.20377319.s6.e3" /></sentence><sentence text=" A bioequivalence approach based on a within-subject comparison was used to investigate a potential drug-drug interaction" /><sentence text=" End/start of treatment geometric mean ratios (GMR, %) and 90% confidence intervals (90% CI) were calculated for maximum plasma concentration (C(max)) and area under the plasma concentration-time curve over the dosing interval at steady-state (AUC(ss)) of eslicarbazepine (ESL major active metabolite), R-licarbazepine (ESL minor active metabolite) and TPM at Day 8 and Day 27"><entity charOffset="256-271" id="DDI-PubMed.20377319.s8.e0" text="eslicarbazepine" /><entity charOffset="303-318" id="DDI-PubMed.20377319.s8.e1" text="R-licarbazepine" /><entity charOffset="273-287" id="DDI-PubMed.20377319.s8.e2" text="ESL" /><entity charOffset="320-334" id="DDI-PubMed.20377319.s8.e3" text="ESL" /><entity charOffset="353-367" id="DDI-PubMed.20377319.s8.e4" text="TPM" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e0" e2="DDI-PubMed.20377319.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e0" e2="DDI-PubMed.20377319.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e0" e2="DDI-PubMed.20377319.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e0" e2="DDI-PubMed.20377319.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e0" e2="DDI-PubMed.20377319.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e2" e2="DDI-PubMed.20377319.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e2" e2="DDI-PubMed.20377319.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e2" e2="DDI-PubMed.20377319.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e2" e2="DDI-PubMed.20377319.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e1" e2="DDI-PubMed.20377319.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e1" e2="DDI-PubMed.20377319.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e1" e2="DDI-PubMed.20377319.s8.e4" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e3" e2="DDI-PubMed.20377319.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s8.e3" e2="DDI-PubMed.20377319.s8.e4" /></sentence><sentence text="" /><sentence text="In Group A, eslicarbazepine GMR (90% CI) was 86"><entity charOffset="12-31" id="DDI-PubMed.20377319.s10.e0" text="eslicarbazepine GMR" /><entity charOffset="37-39" id="DDI-PubMed.20377319.s10.e1" text="CI" /><pair ddi="false" e1="DDI-PubMed.20377319.s10.e0" e2="DDI-PubMed.20377319.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s10.e0" e2="DDI-PubMed.20377319.s10.e1" /></sentence><sentence text="79% (81" /><sentence text="06%; 92" /><sentence text="94%) for C(max) and 92" /><sentence text="70% (89" /><sentence text="21%; 96" /><sentence text="32%) for AUC(ss)" /><sentence text=" In Group B, TPM GMR (90% CI) was 81"><entity charOffset="13-14" id="DDI-PubMed.20377319.s17.e0" text="TPM" /><entity charOffset="26-27" id="DDI-PubMed.20377319.s17.e1" text="CI" /><pair ddi="false" e1="DDI-PubMed.20377319.s17.e0" e2="DDI-PubMed.20377319.s17.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s17.e0" e2="DDI-PubMed.20377319.s17.e1" /></sentence><sentence text="50% (77" /><sentence text="48%; 85" /><sentence text="89%) for C(max) and 81" /><sentence text="81% (79" /><sentence text="69%; 84" /><sentence text="00%) for AUC(ss)" /><sentence text=" The 90% CI of eslicarbazepine C(max) and AUC(ss) fell within the pre-specified bioequivalence range (80"><entity charOffset="15-30" id="DDI-PubMed.20377319.s24.e0" text="eslicarbazepine" /><entity charOffset="9-23" id="DDI-PubMed.20377319.s24.e1" text="CI" /><pair ddi="false" e1="DDI-PubMed.20377319.s24.e1" e2="DDI-PubMed.20377319.s24.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s24.e1" e2="DDI-PubMed.20377319.s24.e0" /></sentence><sentence text="00%; 125" /><sentence text="00%), allowing it to be concluded that the extent of systemic exposure to eslicarbazepine was unaffected by the concomitant administration of TPM"><entity charOffset="74-89" id="DDI-PubMed.20377319.s26.e0" text="eslicarbazepine" /><entity charOffset="142-156" id="DDI-PubMed.20377319.s26.e1" text="TPM" /><pair ddi="false" e1="DDI-PubMed.20377319.s26.e0" e2="DDI-PubMed.20377319.s26.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s26.e0" e2="DDI-PubMed.20377319.s26.e1" /></sentence><sentence text=" The 90% CI for topiramate AUC(ss) was borderline in relation to the pre-specified bioequivalence range and topiramate C(max) fell outside the pre-specified bioequivalence range"><entity charOffset="9-11" id="DDI-PubMed.20377319.s27.e0" text="CI" /><entity charOffset="16-26" id="DDI-PubMed.20377319.s27.e1" text="topiramate" /><entity charOffset="108-118" id="DDI-PubMed.20377319.s27.e2" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.20377319.s27.e0" e2="DDI-PubMed.20377319.s27.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s27.e0" e2="DDI-PubMed.20377319.s27.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s27.e0" e2="DDI-PubMed.20377319.s27.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s27.e1" e2="DDI-PubMed.20377319.s27.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s27.e1" e2="DDI-PubMed.20377319.s27.e2" /></sentence><sentence text=" Therefore, the extent of systemic exposure to TPM following co-administration with ESL was not formally bioequivalent to the extent of systemic exposure to TPM when TPM was administered alone"><entity charOffset="84-93" id="DDI-PubMed.20377319.s28.e0" text="ESL" /><entity charOffset="47-56" id="DDI-PubMed.20377319.s28.e1" text="TPM" /><entity charOffset="157-166" id="DDI-PubMed.20377319.s28.e2" text="TPM" /><entity charOffset="166-175" id="DDI-PubMed.20377319.s28.e3" text="TPM" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e1" e2="DDI-PubMed.20377319.s28.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e1" e2="DDI-PubMed.20377319.s28.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e1" e2="DDI-PubMed.20377319.s28.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e1" e2="DDI-PubMed.20377319.s28.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e0" e2="DDI-PubMed.20377319.s28.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e0" e2="DDI-PubMed.20377319.s28.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e0" e2="DDI-PubMed.20377319.s28.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e2" e2="DDI-PubMed.20377319.s28.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s28.e2" e2="DDI-PubMed.20377319.s28.e3" /></sentence><sentence text=" However, there was no difference between TPM elimination half-life following TPM co-administered with ESL and TPM administered alone (24"><entity charOffset="103-105" id="DDI-PubMed.20377319.s29.e0" text="ESL" /><entity charOffset="42-44" id="DDI-PubMed.20377319.s29.e1" text="TPM" /><entity charOffset="78-80" id="DDI-PubMed.20377319.s29.e2" text="TPM" /><entity charOffset="111-113" id="DDI-PubMed.20377319.s29.e3" text="TPM" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e1" e2="DDI-PubMed.20377319.s29.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e1" e2="DDI-PubMed.20377319.s29.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e1" e2="DDI-PubMed.20377319.s29.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e1" e2="DDI-PubMed.20377319.s29.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e2" e2="DDI-PubMed.20377319.s29.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e2" e2="DDI-PubMed.20377319.s29.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e2" e2="DDI-PubMed.20377319.s29.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e0" e2="DDI-PubMed.20377319.s29.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s29.e0" e2="DDI-PubMed.20377319.s29.e3" /></sentence><sentence text="0 and 24" /><sentence text="3 h, respectively)" /><sentence text=" The bioavailability of R-licarbazepine was essentially bioequivalent"><entity charOffset="24-39" id="DDI-PubMed.20377319.s32.e0" text="R-licarbazepine" /></sentence><sentence text=" Two subjects discontinued due to adverse events" /><sentence text=" No clinical interaction appeared to be present in terms of adverse events when both drugs were given concomitantly" /><sentence text="" /><sentence text="Concomitant administration of eslicarbazepine acetate 1200 mg once daily and topiramate 200 mg once daily showed no significant change in exposure to eslicarbazepine but an 18% decrease in exposure to topiramate, most likely caused by a reduced bioavailability of topiramate"><entity charOffset="30-53" id="DDI-PubMed.20377319.s36.e0" text="eslicarbazepine acetate" /><entity charOffset="77-87" id="DDI-PubMed.20377319.s36.e1" text="topiramate" /><entity charOffset="150-165" id="DDI-PubMed.20377319.s36.e2" text="eslicarbazepine" /><entity charOffset="201-211" id="DDI-PubMed.20377319.s36.e3" text="topiramate" /><entity charOffset="264-274" id="DDI-PubMed.20377319.s36.e4" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e0" e2="DDI-PubMed.20377319.s36.e0" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e0" e2="DDI-PubMed.20377319.s36.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e0" e2="DDI-PubMed.20377319.s36.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e0" e2="DDI-PubMed.20377319.s36.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e0" e2="DDI-PubMed.20377319.s36.e4" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e1" e2="DDI-PubMed.20377319.s36.e1" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e1" e2="DDI-PubMed.20377319.s36.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e1" e2="DDI-PubMed.20377319.s36.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e1" e2="DDI-PubMed.20377319.s36.e4" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e2" e2="DDI-PubMed.20377319.s36.e2" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e2" e2="DDI-PubMed.20377319.s36.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e2" e2="DDI-PubMed.20377319.s36.e4" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e3" e2="DDI-PubMed.20377319.s36.e3" /><pair ddi="false" e1="DDI-PubMed.20377319.s36.e3" e2="DDI-PubMed.20377319.s36.e4" /></sentence><sentence text=" No dose adjustment is required" /><sentence text="" /></document>